Ray Dalio’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.4M | Sell |
10,865
-2,492
| -19% | -$1.1M | 0.02% | 468 |
|
|
2026
Q1 | $5.96M | Sell |
13,357
-14,131
| -51% | -$6.59M | 0.03% | 379 |
|
|
2025
Q4 | $12.5M | Sell |
27,488
-10,836
| -28% | -$4.67M | 0.05% | 299 |
|
|
2025
Q3 | $15M | Buy |
38,324
+3,934
| +11% | +$1.64M | 0.06% | 253 |
|
|
2025
Q2 | $15.3M | Buy |
+34,390
| New | +$15.8M | 0.06% | 212 |
|
|
2025
Q1 | – | Sell |
-710
| Closed | -$286K | – | 806 |
|
|
2024
Q4 | $286K | Sell |
710
-2,742
| -79% | -$1.27M | ﹤0.01% | 634 |
|
|
2024
Q3 | $1.61M | Sell |
3,452
-29,777
| -90% | -$14.3M | 0.01% | 542 |
|
|
2024
Q2 | $15.6M | Sell |
33,229
-101,466
| -75% | -$44M | 0.08% | 187 |
|
|
2024
Q1 | $56.3M | Buy |
134,695
+2,341
| +2% | +$990K | 0.28% | 69 |
|
|
2023
Q4 | $53.9M | Sell |
132,354
-25,995
| -16% | -$9.6M | 0.3% | 65 |
|
|
2023
Q3 | $55.1M | Sell |
158,349
-17,964
| -10% | -$6.28M | 0.33% | 59 |
|
|
2023
Q2 | $62M | Sell |
176,313
-27,963
| -14% | -$9.42M | 0.38% | 54 |
|
|
2023
Q1 | $64.4M | Buy |
204,276
+103,457
| +103% | +$31M | 0.39% | 55 |
|
|
2022
Q4 | $29.1M | Sell |
100,819
-63,172
| -39% | -$19.3M | 0.16% | 119 |
|
|
2022
Q3 | $47.5M | Sell |
163,991
-53,161
| -24% | -$15.3M | 0.24% | 83 |
|
|
2022
Q2 | $61.2M | Buy |
217,152
+187,000
| +620% | +$50.1M | 0.26% | 80 |
|
|
2022
Q1 | $7.87M | Buy |
30,152
+17,735
| +143% | +$4.21M | 0.03% | 352 |
|
|
2021
Q4 | $2.73M | Sell |
12,417
-2,700
| -18% | -$525K | 0.02% | 420 |
|
|
2021
Q3 | $2.74M | Sell |
15,117
-8,139
| -35% | -$1.59M | 0.02% | 387 |
|
|
2021
Q2 | $4.69M | Buy |
23,256
+1,567
| +7% | +$328K | 0.03% | 341 |
|
|
2021
Q1 | $4.66M | Buy |
21,689
+18,059
| +497% | +$3.97M | 0.04% | 228 |
|
|
2020
Q4 | $858K | Buy |
+3,630
| New | +$833K | 0.01% | 405 |
|
|
2019
Q4 | – | Sell |
-32,260
| Closed | -$5.46M | – | 577 |
|
|
2019
Q3 | $5.46M | Buy |
+32,260
| New | +$5.71M | 0.05% | 137 |
|
|
2019
Q2 | – | Sell |
-21,889
| Closed | -$4.03M | – | 369 |
|
|
2019
Q1 | $4.03M | Buy |
+21,889
| New | +$4.04M | 0.02% | 155 |
|
|
2018
Q3 | – | Sell |
-15,509
| Closed | -$2.64M | – | 487 |
|
|
2018
Q2 | $2.64M | Buy |
+15,509
| New | +$2.4M | 0.03% | 181 |
|
|
2017
Q3 | – | Sell |
-18,673
| Closed | -$2.41M | – | 397 |
|
|
2017
Q2 | $2.41M | Buy |
+18,673
| New | +$2.25M | 0.02% | 156 |
|
Other funds holding VRTX
Ray Dalio's VRTX Position: Q2 2026 in Review
Ray Dalio reduced its Vertex Pharmaceuticals (VRTX) stake by 19% in Q2 2026, selling an estimated $1.1M and leaving 10,865 shares worth $5.4M. The position accounts for 0.02% of the portfolio, ranked #468.
Ray Dalio first reported a position in VRTX in Q2 2017 and has held it in 26 quarters since. The position peaked at $64.4M in Q1 2023. 1,766 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Ray Dalio held 10,865 shares of Vertex Pharmaceuticals worth $5.4M as of Q2 2026.
- Ray Dalio sold 2,492 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.1M.
- Vertex Pharmaceuticals made up 0.02% of Ray Dalio's portfolio in Q2 2026, its #468 holding.
- Ray Dalio first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 26 quarters since.
- Ray Dalio's Vertex Pharmaceuticals position peaked at $64.4M in Q1 2023.
- 1,766 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.